S. Barnett

发表

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

D. Nickle, G. Learn, A. Rodrigo, 2005, Journal of Virology.

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen

D. Montefiori, I. Srivastava, C. Greer, 2004, AIDS.

Enhancement of DNA vaccine potency in rhesus macaques by electroporation.

Mark G. Lewis, J. Ulmer, J. Donnelly, 2004, Vaccine.

Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.

M. Magnani, B. Ensoli, I. Srivastava, 2007, Vaccine.

Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

J. Ulmer, I. Srivastava, S. Barnett, 2009, Virology.

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

L. Stamatatos, Loïc Martin, C. Vita, 2003, Journal of Virology.

Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.

T. Kepler, H. Liao, Laura L. Sutherland, 2016, Cell reports.

Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity

T. Kepler, H. Liao, J. Sodroski, 2016, EBioMedicine.

Stabilizing Exposure of Conserved Epitopes by Structure Guided Insertion of Disulfide Bond in HIV-1 Envelope Glycoprotein

E. Go, H. Desaire, D. Montefiori, 2013, PloS one.

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates

B. Korber, D. Montefiori, O. Yang, 2015, Journal of Virology.

HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans

N. Haigwood, H. Schuitemaker, R. Sanders, 2013, PloS one.

An AIDS-like condition induced in baboons by HIV-2.

J. Levy, K. Murthy, S. Barnett, 1994, Science.

Human immunodeficiency virus-2 infection in baboons is an animal model for human immunodeficiency virus pathogenesis in humans.

J. Levy, A. Haase, G. Reyes-Terán, 1998, Archives of pathology & laboratory medicine.

Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin

R. Rappuoli, P. Andersen, D. Novicki, 2009, PloS one.

Structural Constraints of V accine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting

T. Kepler, H. Liao, Laura L. Sutherland, 2015 .

Molecular Evolution Analysis of the Human Immunodeficiency Virus Type 1 Envelope in Simian/Human Immunodeficiency Virus-Infected Macaques: Implications for Challenge Dose Selection

J. Heeney, S. Frost, M. Varela, 2011, Journal of Virology.

Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and 1 Specificities of Antibody Responses against HIV-1 Env in Macaques

D. Montefiori, J. Heeney, G. Ferrari, 2017 .

Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site

D. Montefiori, J. Heeney, G. Ferrari, 2017, Journal of Virology.

Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.

H. Liao, B. Haynes, D. Montefiori, 2015, The Journal of infectious diseases.

Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants

Q. Sattentau, D. Montefiori, J. Heeney, 2012, PloS one.

Comparative Immunogenicity of Subtype A Human Immunodeficiency Virus Type 1 Envelope Exhibiting Differential Exposure of Conserved Neutralization Epitopes

L. Stamatatos, C. Blish, J. Overbaugh, 2009, Journal of Virology.

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

D. Montefiori, N. Letvin, R. Pal, 2008, AIDS.

Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.

J. Heeney, M. Robert-Guroff, I. Srivastava, 2008, Virology.

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.

L. Stamatatos, N. Letvin, J. Heeney, 2006, Virology.

Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes

R. Rappuoli, E. Settembre, C. Ciferri, 2015, Proceedings of the National Academy of Sciences.

Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

S. Self, D. Montefiori, R. Gottardo, 2018, Journal of Virology.

Immunogenicity by Electroporation In Vivo Increased DNA Vaccine Delivery and

J. Ulmer, M. Selby, D. Rabussay, 2000 .

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period

D. Montefiori, S. Kalams, M. McElrath, 2019, The Journal of infectious diseases.

Efforts to broaden HIV‐1‐specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus

J. Heeney, B. Rosenwirth, S. Barnett, 1999, Journal of medical primatology.

Characterization of the South African HIV type 1 subtype C complete 5' long terminal repeat, nef, and regulatory genes.

T. Scriba, S. Barnett, S. Engelbrecht, 2002, AIDS research and human retroviruses.

Nonviral delivery of self-amplifying RNA vaccines

Thomas Krucker, Rino Rappuoli, Yen Cu, 2012, Proceedings of the National Academy of Sciences.

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake

R. Koup, N. Sullivan, E. De Gregorio, 2017, Science Translational Medicine.

Infection of Human Dendritic Cells by a Sindbis Virus Replicon Vector Is Determined by a Single Amino Acid Substitution in the E2 Glycoprotein

D. Driver, M. L. Mackichan, B. Belli, 2000, Journal of Virology.

Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer Antibodies

D. Montefiori, D. Venzon, M. Robert-Guroff, 2005, Journal of Virology.

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

L. Stamatatos, Z. Kraft, I. Srivastava, 2006, Virology.

Chapter 15. DNA Vaccines Coming of Age

Margaret A. Liu, S. Barnett, 1999 .

Cloning SV40 HindIII restriction fragments into M13 bacteriophage.

S. Barnett, C. Lau, K. Dixon, 1982, Gene.

A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

S. Moretti, B. Ensoli, I. Srivastava, 2011, Vaccine.

Induction of immunodeficiency virus‐specific immune responses in rhesus monkeys following gene gun‐mediated DNA vaccination

J. Clements, D. Fuller, M. Murphey-Corb, 1996, Journal of medical primatology.

Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.

P. Luciw, J. Donnelly, C. Greer, 2006, AIDS research and human retroviruses.

Characterization of Human Immunodeficiency Virus Gag-Specific Gamma Interferon-Expressing Cells following Protective Mucosal Immunization with Alphavirus Replicon Particles

P. Luciw, J. Donnelly, C. Greer, 2005, Journal of Virology.

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.

C. Mandl, P. Mason, R. Loomis, 2013, Vaccine.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

J. Kublin, D. Montefiori, N. Frahm, 2018, The lancet. HIV.

Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo

J. Ulmer, M. Selby, D. Rabussay, 2000, The Journal of Immunology.

Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines

J. Ulmer, Manmohan J. Singh, M. Schaefer, 2001, Journal of Virology.

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

D. Montefiori, D. Venzon, G. Alter, 2019, PLoS pathogens.

An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains

D. Montefiori, D. Venzon, M. Robert-Guroff, 2006, Journal of acquired immune deficiency syndromes.

Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein.

L. Stamatatos, Z. Kraft, I. Srivastava, 2006, AIDS research and human retroviruses.

Material for Adjuvant dependent innate and adaptive immune signatures of risk of SIVmac 251 acquisition

Karen G. Dowell, Christopher J. Miller, C. Bailey-Kellogg, 2016 .

β7‐integrin‐independent enhancement of mucosal and systemic anti‐HIV antibody responses following combined mucosal and systemic gene delivery

P. Luciw, J. Donnelly, Manmohan J. Singh, 2007, Immunology.

CD8+ cells from HIV‐2‐infected baboons control HIV replication

J. Levy, K. Murthy, K. Brasky, 1997, AIDS.

An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates

S. Zolla-Pazner, N. Sardesai, D. Weiner, 2015, Journal of Virology.

Studies of HIV‐1 envelope glycoprotein‐mediated fusion using a simple fluorescence assay

D. Littman, N. Killeen, J. White, 1996, AIDS.

Infection of baboons with a simian immunodeficiency virus/HIV‐1 chimeric virus constructed with an HIV‐1 Thai subtype E envelope

P. Luciw, J. Klinger, S. Barnett, 1998, AIDS.

Human immunodeficiency viruses.

L. Stamatatos, J. Levy, E. Barker, 1996, IARC monographs on the evaluation of carcinogenic risks to humans.

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study

D. Montefiori, R. Gottardo, G. Pantaleo, 2022, Frontiers in Immunology.

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost

S. Self, D. Montefiori, R. Gottardo, 2018, Journal of Virology.

Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa

E. Go, H. Desaire, H. Liao, 2016, PloS one.

Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain

J. Levy, S. Barnett, A. Werner, 1993, Journal of virology.

Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.

Peter W Mason, P. Mason, A. Carfi, 2014, Vaccine.

Proceedings of the Frontiers of Retrovirology Conference 2016

R. König, D. Elleder, R. Sachidanandam, 2016, Retrovirology.

Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Daniel E. Zak, Carrie D. Johnson, D. Zak, 2017, Blood advances.

A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime With Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost

Jerome H. Kim, D. Birx, R. Paris, 2007, Journal of acquired immune deficiency syndromes.

Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance

J. Heeney, D. Fuller, M. van der Kolk, 1999, Journal of Virology.

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations.

D. Montefiori, P. Luciw, J. Donnelly, 2004, AIDS research and human retroviruses.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Karen G. Dowell, Jerome H. Kim, C. Bailey-Kellogg, 2016, Nature Medicine.

Test of models for replication of simian virus 40 DNA following ultraviolet irradiation.

E. Landaw, S. Barnett, K. Dixon, 1984, Biophysical journal.

Problems and emerging approaches in HIV/AIDS vaccine development

M. Robert-Guroff, S. Moretti, R. Gavioli, 2007, Expert opinion on emerging drugs.

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.

David C Montefiori, Susan Zolla-Pazner, Nelson L Michael, 2008, Virology.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

C. Mandl, P. Dormitzer, P. Mason, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

A Fusion Intermediate gp41 Immunogen Elicits Neutralizing Antibodies to HIV-1*

D. Montefiori, W. Weissenhorn, J. Heeney, 2014, The Journal of Biological Chemistry.

HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine

W. Borkowsky, M. McElrath, Y. Fong, 2017, Journal of Virology.

Increased Expression and Immunogenicity of Sequence-Modified Human Immunodeficiency Virus Type 1 gag Gene

Mary Schaefer, Mark Selby, C. Greer, 2000, Journal of Virology.

Expression and Immunogenicity of Sequence-Modified Human Immunodeficiency Virus Type 1 Subtype B pol and gagpol DNA Vaccines

J. Ulmer, J. Donnelly, Hong Liu, 2003, Journal of Virology.

Putative role of Tat–Env interaction in HIV infection

L. Xing, P. Kolatkar, R. Cheng, 2013, AIDS.

Design Platforms of Nanocapsules for Human Therapeutics or Vaccines

K. Lam, L. Xing, H. Handa, 2011 .

Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells

Dina N. Kovarik, N. Haigwood, D. Montefiori, 2012, PloS one.

Role of Neutralizing Antibodies in Protective Immunity Against HIV

J. Ulmer, I. Srivastava, S. Barnett, 2005, Human vaccines.

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design

J. Ulmer, I. Srivastava, S. Barnett, 2004, Expert review of vaccines.

Noncoordinate expression of Drosophila glue genes: Sgs-4 is expressed at many stages and in two different tissues.

M. K. Webster, S. Barnett, S. Beckendorf, 1990, Developmental biology.

Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus

L. Stamatatos, J. Ulmer, J. Donnelly, 2002, Journal of Virology.

Prevalence of Dirofilaria immitis (Nematoda: Filarioidea) in Mosquitoes from Northeast Arkansas, the United States

S. Barnett, T. Mckay, T. Bianco, 2013, Journal of medical entomology.

Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge

D. Montefiori, D. Venzon, M. G. Ferrari, 2015, PLoS pathogens.

Novel evolutionary analyses of full-length HIV type 1 subtype C molecular clones from Cape Town, South Africa.

T. de Oliveira, T. Scriba, S. Barnett, 2002, AIDS research and human retroviruses.

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

J. Kublin, D. Montefiori, L. Morris, 2016, PloS one.

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap

D. Montefiori, L. Morris, C. Williamson, 2016, Clinical and Vaccine Immunology.

Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.

J. Ulmer, J. Donnelly, D. Rabussay, 2006, Vaccine.

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.

R. Gavioli, A. Caputo, B. Ensoli, 2008, Vaccine.

Sequential Immunization with a Subtype B HIV-1 Envelope Quasispecies Partially Mimics the In Vivo Development of Neutralizing Antibodies

N. Haigwood, L. Stamatatos, N. Doria-Rose, 2011, Journal of Virology.

Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences.

T. Scriba, S. Barnett, R. Glashoff, 2005, Vaccine.

Transient virus infection and pathogenesis of a new HIV type 2 isolate, UC12, in baboons.

J. Levy, G. Reyes-Terán, K. Murthy, 1998, AIDS research and human retroviruses.

Superinfection with human immunodeficiency virus type 2 can reactivate virus production in baboons but is contained by a CD8 T cell antiviral response.

J. Levy, G. Reyes-Terán, K. Murthy, 1997, The Journal of infectious diseases.

Biologic heterogeneity of human immunodeficiency virus type 2 (HIV-2) strains.

J. Levy, S. Barnett, L. Evans, 1990, Virology.

Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.

P. Spearman, Xuemin Chen, S. Barnett, 2003, Virology.

Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.

D. Venzon, M. Robert-Guroff, S. Kuate, 2010, Vaccine.

Evaluation of Envelope Vaccines Derived from the South African Subtype C Human Immunodeficiency Virus Type 1 TV1 Strain

D. Montefiori, P. Luciw, J. Ulmer, 2005, Journal of Virology.

Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region

L. Stamatatos, I. Srivastava, S. Barnett, 2003, Journal of Virology.

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults

M. Andrasik, J. Kublin, M. McElrath, 2021, The New England journal of medicine.

A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.

Brigitte E. Sanders-Beer, J. Ulmer, J. Donnelly, 2008, AIDS research and human retroviruses.

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Yide Sun, L. Stamatatos, J. Ulmer, 2006, Virology.

Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.

D. Montefiori, D. Venzon, Stanley Aladi, 2013, Virology.

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

D. Montefiori, D. Venzon, G. Alter, 2019, PLoS pathogens.

Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

D. Montefiori, J. Heeney, I. Srivastava, 2012, Vaccine.

HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies

R. Rappuoli, K. Montin, F. Dallocchio, 2012, PloS one.

Molecular cloning of the human immunodeficiency virus subtype 2 strain HIV-2UC2.

J. Levy, Y. Sun, S. Barnett, 1996, Virology.

Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant

J. Ulmer, J. Donnelly, I. Srivastava, 2010, Journal of Virology.

Cross-Subtype Neutralizing Antibodies Induced in Baboons by a Subtype E gp120 Immunogen Based on an R5 Primary Human Immunodeficiency Virus Type 1 Envelope

J. Mascola, M. Robb, D. Birx, 1999, Journal of Virology.

Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles

J. Ulmer, J. Donnelly, Manmohan J. Singh, 2003, Journal of Virology.

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Prima

S. Self, D. Montefiori, R. Gottardo, 2017, Journal of Virology.

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

S. Self, D. Montefiori, G. Pantaleo, 2015, Journal of Virology.

Quantitative assessment of antigen-specific CD8+ T cells in the mouse: application to vaccine research.

J. Ulmer, G. Otten, S. Barnett, 2003, Immunology letters.

Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk

Haiyan Chen, H. Liao, B. Haynes, 2013, Journal of Virology.

Differential pathogenicity of SHIVSF162 P4 infection in pig‐tailed and rhesus macaques

L. Stamatatos, Z. Kraft, Shiu-Lok Hu, 2008, Journal of medical primatology.

Lack of Interference with Immunogenicity of a Chimeric Alphavirus Replicon Particle-Based Influenza Vaccine by Preexisting Antivector Immunity

R. Rappuoli, Y. Uematsu, C. Greer, 2012, Clinical and Vaccine Immunology.

Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates

Xiaoying Shen, G. Tomaras, R. Shattock, 2016, Journal of Virology.

Variability at Human Immunodeficiency Virus Type 1 Subtype C Protease Cleavage Sites: an Indication of Viral Fitness?

Tulio de Oliveira, Susan Engelbrecht, T. de Oliveira, 2003, Journal of Virology.

Dynamics of acute and memory mucosal and systemic immune responses against HIV‐1 envelope following immunizations through single or combinations of mucosal and systemic routes

I. Srivastava, S. Barnett, M. Vajdy, 2008, Vaccine.

Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization

T. Kepler, J. Mullikin, J. Mascola, 2015, Nature Communications.

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

Rachel L. Spreng, P. Gilbert, L. Corey, 2020, Scientific Reports.

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

D. Montefiori, M. McElrath, L. Corey, 2011, The Journal of infectious diseases.

Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

N. Haigwood, H. Robins, S. Barnett, 2014, Vaccine.

Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ

N. Sardesai, J. Ulmer, G. Otten, 2013, Vaccines.

Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals.

J. Levy, C. Forsmark, C. Wilcox, 1991, Virology.

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

S. Self, D. Montefiori, R. Gottardo, 2016, Journal of Virology.

Streamlining Heterologous DNA-Prime and NYVAC / Protein-Boost HIV Vaccine Regimens in 1 Rhesus Macaques by Employing Improved Antigens 2 3

S. Self, D. Montefiori, R. Gottardo, 2016 .

Structural Evidence of Glycoprotein Assembly in Cellular Membrane Compartments prior to Alphavirus Budding

Pan Soonsawad, R. Holland Cheng, Michael Marko, 2010, Journal of Virology.

Prime-boost immunization strategies against HIV.

C. Walker, F. Sinangil, S. Barnett, 1998, AIDS research and human retroviruses.

Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.

L. Stamatatos, R. Diaz-Avalos, R. Cheng, 2008, Virology.

Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.

J. Ulmer, J. Donnelly, C. Greer, 2006, Vaccine.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant

Jerome H. Kim, H. Liao, B. Haynes, 2018, PloS one.

DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies

D. Montefiori, C. Gray, G. Ferrari, 2017, Vaccine.

Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection

L. Stamatatos, J. Binley, Z. Kraft, 2006, Journal of Virology.

The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region

J. Mascola, L. Stamatatos, A. Gettie, 2001, Journal of Virology.

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

Allan C. deCamp, J. Kublin, S. Omarjee, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops

L. Xing, L. Paavolainen, R. Cheng, 2014, Scientific Reports.

Elicits Neutralizing Antibodies to HIV-1 A Fusion Intermediate gp 41 Immunogen Microbiology

Ralf, Jens, W. Weissenhorn, 2014 .

Elicitation of Neutralizing Antibodies Directed against CD4-Induced Epitope(s) Using a CD4 Mimetic Cross-Linked to a HIV-1 Envelope Glycoprotein

D. Montefiori, Klára Sirokmán, A. Carfi, 2012, PloS one.

Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding

L. Xing, R. Cheng, I. Srivastava, 2011, Proceedings of the National Academy of Sciences.

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

J. Mascola, G. Nabel, Srinivas S. Rao, 2007, Vaccine.

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.

R. Gavioli, A. Caputo, B. Ensoli, 2008, Vaccine.

Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa.

S. Barnett, S. Engelbrecht, J. Z. Megede, 2001, AIDS research and human retroviruses.

Structural Characteristics Predict the Stability of HIV

J. Ulmer, I. Srivastava, M. Franti, 2011 .

Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

L. Stamatatos, Z. Kraft, E. Wayner, 2007, Virology.

Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.

R. Rappuoli, J. Ulmer, J. Donnelly, 2005, Microbes and infection.

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

L. Stamatatos, A. Gettie, J. Blanchard, 2004, Virology.

DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques.

D. Ho, L. Stamatatos, X. Jin, 2001, Immunology letters.

DNA Vaccination with the Human Immunodeficiency Virus Type 1 SF162ΔV2 Envelope Elicits Immune Responses That Offer Partial Protection from Simian/Human Immunodeficiency Virus Infection to CD8+ T-Cell-Depleted Rhesus Macaques

D. Ho, L. Stamatatos, X. Jin, 2001, Journal of Virology.

Polypeptides vih env modifies

K. Hartog, S. Barnett, E. E. Martin, 1999 .

Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.

J. Heeney, G. Vanham, S. Barnett, 2004, Vaccine.

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein

D. Montefiori, C. Labranche, I. Srivastava, 2015, PloS one.

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens

Jerome H. Kim, C. Andrews, M. Robb, 2015, AIDS research and human retroviruses.

Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins

D. Montefiori, T. Dubensky, D. Driver, 2005, Journal of Virology.

Broadening our view of protective antibody responses against HIV.

S. Barnett, B. Burke, 2007, Current HIV research.

Stabilization of HIV-1 Envelope in the CD4-bound Conformation through Specific Cross-linking of a CD4 Mimetic*

D. Montefiori, R. Guérois, Hocine Madaoui, 2011, The Journal of Biological Chemistry.

Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic.

D. Montefiori, R. Guérois, Hocine Madaoui, 2011, The Journal of Biological Chemistry.

A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.

J. Ulmer, I. Srivastava, S. Barnett, 2008, Virology.

Envelope-Based HIV Vaccines

L. Stamatatos, J. Donnelly, A. Dorenbaum, 2002, Science.

Proceedings of the Frontiers of Retrovirology Conference 2016

Sebastian A. Wagner, R. König, D. Elleder, 2016, Retrovirology.

Species tropism of chimeric SHIV clones containing HIV-1 subtype-A and subtype-E envelope genes.

P. Luciw, S. Barnett, G. Douglas, 2002, Virology.

Antibody mediated protection of immunized macaques against pathogenic SHIV challenge

L. Stamatatos, J. Ulmer, J. Donnelly, 2006, Retrovirology.

Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions

A. Carfi, C. Lorin, M. Koutsoukos, 2016, Vaccines.

Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques

D. Montefiori, J. Heeney, G. Ferrari, 2017, Journal of Virology.

L. Stamatatos, J. Binley, Z. Kraft, 2007, Journal of Virology.

Developmental regulation by an enhancer from the Sgs‐4 gene of Drosophila

S. Barnett, S. Beckendorf, Antony W. Shermoen, 1987, The EMBO journal.

Nonviral delivery of self-amplifying RNA vaccines

C. Mandl, R. Rappuoli, P. Dormitzer, 2012, Proceedings of the National Academy of Sciences.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

C. Mandl, P. Dormitzer, P. Mason, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.

S. Zolla-Pazner, D. Dimitrov, D. Montefiori, 2008, Virology.

Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding

L. Xing, R. Cheng, I. Srivastava, 2011, Proceedings of the National Academy of Sciences.

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

K. Steimer, C. Walker, D. Fuller, 1997, Vaccine.

Comparison of intranasal with targeted lymph node immunization using PR8‐Flu ISCOM adjuvanted HIV antigens in macaques

T. Lehner, J. Heeney, S. Barnett, 2007, Journal of medical virology.

A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

S. Moretti, B. Ensoli, I. Srivastava, 2011, Vaccine.